Protection from influenza virus challenge.

Slides:

Advertisements

Similar presentations

In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections Chasity D. Andrews,

Advertisements

Shigella-specific serum IgG and IgA endpoint titers in guinea pigs immunized intranasally with S. flexneri 2a InvaplexNAT or InvaplexAR. Shigella-specific.

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Serum IgG (A–D) and IgA (E–H) titer from BALB/c mice (n = 5/group) at day 0 or following COBRA P1 virus i.n., i.p., or i.m. prime at day 21 or following.

Volume 25, Issue 6, Pages (June 2017)

Targeted DNA vaccination induced protection against nasal challenge with influenza virus 14 d after DNA vaccination. Targeted DNA vaccination induced protection.

Breadth of binding and HAI activity of serum Ab from i. n. + i. p

Survival of mice after infection with M

(A) Weight loss curves following intranasal infection of different mouse groups with COBRA, seasonal, or pandemic influenza viruses. (A) Weight loss curves.

Long-lasting protection against nasal challenge with influenza virus 252 d after a single DNA vaccination. Long-lasting protection against nasal challenge.

FMDV-specific IgG, IgG1, and IgG2 in sera of guinea pigs (n = 6/group) immunized on days 1 and 21 by intramuscular injection of FMDV antigens (type O)

A single DNA vaccination of C57BL/6 mice induced Ab responses of IgG1 and/or IgG2c subclass. A single DNA vaccination of C57BL/6 mice induced Ab responses.

Serum IgG subclass representation from BALB/c mice (n = 5/group) following COBRA P1 virus i.n., i.p., or i.m. prime followed by i.p. or i.m. boost. Serum.

Virus-specific serum antibody response of BALB/c mice to DNA prime followed by VRP boost. Virus-specific serum antibody response of BALB/c mice to DNA.

Prf1−/− mice exhibit increased immunopathology with prior CD8 T cell memory secondary to immunization. Prf1−/− mice exhibit increased immunopathology with.

FMD VP1-specific IgG, IgG1, and IgG2 in sera of guinea pigs (n = 6/group) immunized on days 1 and 21 by intramuscular injection of FMDV antigens (type.

Detection of CSFV-specific antibodies in immunized/challenged pigs using blocking ELISA. Groups of pigs (n = 5) were inoculated with different doses of.

Virus-specific serum antibody response of BALB/c mice to DNA prime followed by VRP boost. Virus-specific serum antibody response of BALB/c mice to DNA.

Immune response to vaccination with AVA in healthy human subjects (human immunogenicity study). Immune response to vaccination with AVA in healthy human.

Survival of BALB/c mice after HK/Syd challenge.

Relationship between prechallenge AVA-induced TNA levels and probability of animal survival following lethal challenge with B. anthracis spores in rabbit.

Serum neutralizing antibody response of BALB/c mice to DNA prime followed by VRP boost. Serum neutralizing antibody response of BALB/c mice to DNA prime.

Survival and time to death of NZW rabbits following vaccination with AVA and subsequent lethal B. anthracis spore challenge (rabbit preexposure prophylaxis.

Comparison of relative activity of Adjuplex and other commonly used adjuvants. Comparison of relative activity of Adjuplex and other commonly used adjuvants.

In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections Chasity D. Andrews,

Survival of NZW rabbits following lethal B

Immune response to vaccination with AVA in NZW rabbits (rabbit preexposure prophylaxis study). Immune response to vaccination with AVA in NZW rabbits (rabbit.

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

Antibody endpoint titers induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.5% to 2% (vol/vol) oil, as measured.

Survival and time to death of cynomolgus macaques following vaccination with AVA and subsequent lethal B. anthracis spore challenge (NHP preexposure prophylaxis.

Longevity of mucosal and systemic antibody responses induced by pulmonary vaccination. Longevity of mucosal and systemic antibody responses induced by.

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Antitumor effect of local cancer immunotherapy treatment in various tumor models. Antitumor effect of local cancer immunotherapy treatment in various tumor.

Protective effects of cysteine protease inhibitor Z-FA-FMK and E64d in SMNΔ7 mice. Protective effects of cysteine protease inhibitor Z-FA-FMK and E64d.

Pulmonary vaccination induces a long-term immune memory response to antigen challenge. Pulmonary vaccination induces a long-term immune memory response.

Immune response to vaccination with AVA in cynomolgus macaques (NHP preexposure prophylaxis study). Immune response to vaccination with AVA in cynomolgus.

Reproducibility of LPA results for cryopreserved PBMC after variable periods of storage in liquid nitrogen. Reproducibility of LPA results for cryopreserved.

OVA-specific and InvaplexNAT-specific serum IgG endpoint titers in mice after intranasal immunization with OVA alone or OVA combined with InvaplexAR, InvaplexNAT,

Vaccine MN confer protective innate and adaptive immunity.

Prime and boosts with PBK001 vaccine provided 100% protection with low bacterial burden in organs. Prime and boosts with PBK001 vaccine provided 100% protection.

Antibody endpoint titers induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.02% to 2% (vol/vol) oil, as measured.

Trained immunity induction of glycolysis.

Intranasal immunization of mice with S

Cross-protection against variants within a subtype after intranasal immunization with vaccine from MDCK cell-adapted Vac-3 P22. Cross-protection against.

Antibody titers against surface antigens of B

Trained immunity effects on cell morphology and numbers.

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

RTA pepscan analysis of sera from RiVax- and RVEc-immunized mice.

Kaplan-Meier survival curves for canine patients with (n = 3; huTyr Ab+) and without (n = 6; huTyr Ab-) positive humoral responses to the xenogeneic huTyr.

Functional characterization of multidonor class antibodies.

Immunization regimens that include a GLA-SE-formulated protein vaccine generate memory CD4 T cells. Immunization regimens that include a GLA-SE-formulated.

Fig. 6 Multivalent DNA vaccine and protein antigen delivery by T4-AAV nanoparticles. Multivalent DNA vaccine and protein antigen delivery by T4-AAV nanoparticles.

RTA-specific serum IgG antibody titers and TNA in mice immunized with RiVax or RVEc. RTA-specific serum IgG titers after the second (A) or third (B) immunizations.

Dilution of anti-C6 monoclonal antibody shows the broader linear range of the Multiplex assay in comparison to standard ELISA. Shown is the dilution of.

Reproducibility of CD4+ and CD8+ T-cell enumeration with cryopreserved PBMC after variable periods of storage in liquid nitrogen. Reproducibility of CD4+

Antibody titers against surface antigens of M

Relation between the total white blood count and the absolute lymphocyte count prior to the first vaccination and the response to vaccination. Relation.

B- and T-cell activity induced by immunization.

Long-lived antibody-secreting cells in the bone marrow, induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.02%

Long-lived antibody-secreting cells in the bone marrow, induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.5%

Time to culling for mastitis among J5 vaccinates and controls

Antigen-specific cytokine production detected by multiplex bead assay (Luminex) 3 weeks after the 3rd immunization. Antigen-specific cytokine production.

Antigen-specific cytokine-producing cells (IFN-γ and IL-5) detected by ELISPOT assay 3 weeks after the 3rd immunization. Antigen-specific cytokine-producing.

Anti-PT IgG results from 227 patients with coughs of unknown etiology who reported the severity of cough on a scale from 0 to 10. Anti-PT IgG results from.

Comparison of quantitative results obtained with the Enzygnost antiVZV/IgG, Serion ELISA Classic VZV IgG, and Euroimmun anti-VZV ELISA (IgG) tests for.

Lkt antibody titers of vaccinated and control groups of BHS

Time to culling for all reasons among J5 vaccinates and controls

Distribution of responses to vaccine antigens in the culture-positive individual group and the control group. Distribution of responses to vaccine antigens.

Lack of innate immune cell and receptor triggering by Adjuplex.

Variability between laboratories in titer estimations (expressed as GCV on the y axis) tends to be higher for samples in low measurement ranges and to.

Presentation transcript:

Protection from influenza virus challenge. Protection from influenza virus challenge. (a) Mice (C57BL/6, 5 per group) were immunized on day 0 with Adjuplex or 0.5 μg of HA alone or HA formulated in Adjuplex, MPL, or alum, and mice were challenged on day 15 after immunization with 16 HAU, corresponding to 1.17 × 105 PFU, of H1N1 PR8 influenza A virus. Weight loss was measured over 10 days and is expressed as the percent change from the starting weight, which was set at 100%. (b) Kaplan-Meier survival curves for each group: mice losing ≥25% of their weight were humanely sacrificed. (c) Weight change over the period of measurement was calculated using AUC analysis. (d) Blood was taken on the day of challenge, and HA-specific serum IgG endpoint titers were determined. (e) Hemagglutination inhibition (HI) titers were determined and are expressed as log2 values. (f) Linear regression analysis of correlation between weight loss and antigen-specific IgG titer. (g) Linear regression analysis of correlation between weight loss and HI titer. (a and c to e) Data are expressed as the mean ± SEM. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Frank Wegmann et al. Clin. Vaccine Immunol. 2015; doi:10.1128/CVI.00736-14